TROY STILES: Open Payments
NPI 1437122207 · BILLINGS, MT. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$75,536 in 116 payments from 11 companies in 2025. Trend: 2023 $54,746 · 2024 $24,712 · 2025 $75,536
Speaker / faculty: $64,442Travel & lodging: $4,754Consulting: $4,530Food & beverage: $1,699Education: $111
| Company | Payments | Amount |
|---|---|---|
| Teva Pharmaceuticals USA, Inc. | 58 | $50,068 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 26 | $24,829 |
| Otsuka America Pharmaceutical, Inc. | 9 | $147 |
| Janssen Pharmaceuticals, Inc | 5 | $109 |
| Neurocrine BioSciences, Inc. | 3 | $81 |
| Vanda Pharmaceuticals Inc. | 4 | $80 |
| Alkermes, Inc. | 3 | $59 |
| ABBVIE INC. | 2 | $55 |
| Collegium Pharmaceutical, Inc. | 2 | $45 |
| Lundbeck LLC | 2 | $36 |
Products named: AUSTEDO XR, CAPLYTA, UZEDY, REXULTI, INVEGA, INGREZZA, FANAPT, ARISTADA.
Industry payments across MT — which companies pay providers there.
